(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/061931 A1

(51) International Patent Classification:
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/EP2022/078084

(22) International Filing Date:
10 October 2022 (10.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2021/078022
11 October 2021 (11.10.2021) EP
PCT/EP2022/050135
05 January 2022 (05.01.2022) EP

(71) Applicants: **BIONTECH SE** [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE). **TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH** [DE/DE]; Freiligrathstrasse 12, 55131 Mainz (DE).

(72) Inventors: **SAHIN, Ugur**; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE). **WEBER, David**; Hasengartenstraße 32A, 65189 Wiesbaden (DE). **WALTER, Carina**; Mainzer Straße 137b, 55124 Mainz (DE). **BAREA ROLDÁN, Diana**; In den Weingärten 1, 67577 Alsheim (DE). **KUNER, Ruprecht**; Nellinger Straße 26, 73760 Ostfildern (DE). **HEIN, Melanie**; Hinter der Hecke 52, 55129 Mainz (DE). **SUCHAN, Martin**; Mainzer Str. 79, 55129 Mainz (DE). **KISSLER, Verena**; Nordelsheimer Weg 12, 55278 Undenheim (DE). **KRANZ, Lena Mareen**; Lorsbacher Straße 9, 65719 Hofheim am Taunus (DE).

(74) Agent: **SCHNAPPAUF, Georg**; Zwicker Schnappauf & Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2023/061931 A1

(54) Title: THERAPEUTIC RNA FOR LUNG CANCER

(57) Abstract: This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.